These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35780032)

  • 1. Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF.
    Butler J; Shahzeb Khan M; Lindenfeld J; Abraham WT; Savarese G; Salsali A; Zeller C; Peil B; Filippatos G; Ponikowski P; Anker SD
    JACC Heart Fail; 2022 Sep; 10(9):651-661. PubMed ID: 35780032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.
    Butler J; Spertus JA; Bamber L; Khan MS; Roessig L; Vlajnic V; Norquist JM; Anstrom KJ; Blaustein RO; Lam CSP; Armstrong PW;
    Eur J Heart Fail; 2022 May; 24(5):843-850. PubMed ID: 35274420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin.
    Mohebi R; Jones PG; Spertus JA; Lingvay I; Lanfear DE; Gosch KL; Birmingham M; Kosiborod MN; Butler J; Januzzi JL
    JACC Heart Fail; 2024 Apr; 12(4):711-718. PubMed ID: 38385941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
    Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
    Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
    JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.
    Butler J; Khan MS; Mori C; Filippatos GS; Ponikowski P; Comin-Colet J; Roubert B; Spertus JA; Anker SD
    Eur J Heart Fail; 2020 Jun; 22(6):999-1005. PubMed ID: 32239794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.
    Yang M; Kondo T; Adamson C; Butt JH; Abraham WT; Desai AS; Jering KS; Køber L; Kosiborod MN; Packer M; Rouleau JL; Solomon SD; Vaduganathan M; Zile MR; Jhund PS; McMurray JJV
    Eur J Heart Fail; 2023 Sep; 25(9):1606-1618. PubMed ID: 37401511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
    JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
    Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence.
    Huang W; Teng TK; Tay WT; Richards AM; Kadam U; Lawson CA; Shimizu W; Loh SY; Anand I; Lam CSP
    ESC Heart Fail; 2020 Oct; 7(5):2051-2062. PubMed ID: 32862518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes.
    Yee D; Novak E; Platts A; Nassif ME; LaRue SJ; Vader JM
    Am J Cardiol; 2019 Mar; 123(5):807-812. PubMed ID: 30587373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction.
    Mentz RJ; Whellan DJ; Reeves GR; Pastva AM; Duncan P; Upadhya B; Nelson MB; Chen H; Reed SD; Rosenberg PB; Bertoni AG; O'Connor CM; Kitzman DW
    JACC Heart Fail; 2021 Oct; 9(10):747-757. PubMed ID: 34246602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
    Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
    Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
    Butler J; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Dorigotti F; Metra M; Piña IL; Coats AJS; Rosano G; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Anker SD; Ponikowski P
    Eur J Heart Fail; 2022 May; 24(5):821-832. PubMed ID: 35279929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health status across major subgroups of patients with heart failure and preserved ejection fraction.
    Siddiqi TJ; Anker SD; Filippatos G; Ferreira JP; Pocock SJ; Böhm M; Brueckmann M; Chopra VK; Iwata T; Januzzi J; Piña IL; Ponikowski P; Senni M; Vedin O; Verma S; Zhang Y; Zannad F; Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1623-1631. PubMed ID: 36974746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
    Abraham WT; Lindenfeld J; Ponikowski P; Agostoni P; Butler J; Desai AS; Filippatos G; Gniot J; Fu M; Gullestad L; Howlett JG; Nicholls SJ; Redon J; Schenkenberger I; Silva-Cardoso J; Störk S; Krzysztof Wranicz J; Savarese G; Brueckmann M; Jamal W; Nordaby M; Peil B; Ritter I; Ustyugova A; Zeller C; Salsali A; Anker SD
    Eur Heart J; 2021 Feb; 42(6):700-710. PubMed ID: 33351892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.
    Joseph SM; Novak E; Arnold SV; Jones PG; Khattak H; Platts AE; Dávila-Román VG; Mann DL; Spertus JA
    Circ Heart Fail; 2013 Nov; 6(6):1139-46. PubMed ID: 24130003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
    Kaul P; Rathwell S; Lam CSP; Westerhout CM; Spertus JA; Anstrom KJ; Blaustein RO; Ezekowitz JA; Pieske B; Roessig L; Butler J; Armstrong PW;
    JACC Heart Fail; 2023 Apr; 11(4):392-403. PubMed ID: 36881394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.